Cargando…
Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (alloSCT) is the sole curative option for myelofibrosis (MF). However, it is unknown as to which of the two, myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC), is a better preconditioning regimen. METHODS: Twenty-f...
Autores principales: | Kim, Dong Hyun, Seo, Jeongmin, Shin, Dong-Yeop, Koh, Youngil, Hong, Junshik, Kim, Inho, Yoon, Sung-Soo, Byun, Ja Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812723/ https://www.ncbi.nlm.nih.gov/pubmed/36450367 http://dx.doi.org/10.5045/br.2022.2022194 |
Ejemplares similares
-
Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin
por: Seo, Jeongmin, et al.
Publicado: (2021) -
Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
por: Park, Hyunkyung, et al.
Publicado: (2020) -
Should patients receive consolidation chemotherapy before reduced
intensity allogeneic hematopoietic stem cell transplantation for acute myeloid
leukemia in first complete remission?
por: Byun, Ja Min, et al.
Publicado: (2021) -
Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation
por: Park, Woochan, et al.
Publicado: (2023) -
Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)